Wells Fargo & Company Forma Therapeutics Holdings, Inc. Transaction History

Wells Fargo & Company

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$7.12 - $20.24 $2,634 - $7,488	-370 Reduced 51.25%	352 $7,000
Q2 2022 Aug 12, 2022	SELL	$5.1 - $10.0 $14,070 - $27,590	-2,759 Reduced 79.26%	722 $5,000
Q1 2022 May 16, 2022	SELL	$8.34 - $14.69 $107,544 - $189,427	-12,895 Reduced 78.74%	3,481 $33,000
Q4 2021 Feb 14, 2022	BUY	$13.6 - $24.89 $120,251 - $220,077	8,842 Added 117.36%	16,376 $232,000
Q3 2021 Nov 15, 2021	SELL	$21.22 - $25.7 $860,831 - $1.04 Million	-40,567 Reduced 84.34%	7,534 $175,000
Q2 2021 Aug 16, 2021	BUY	$22.86 - $30.95 $1.07 Million - $1.45 Million	46,691 Added 3311.42%	48,101 $1.2 Million
Q1 2021 May 13, 2021	SELL	$24.58 - $42.82 $569,002 - $991,240	-23,149 Reduced 94.26%	1,410 $40,000
Q4 2020 Feb 09, 2021	BUY	$34.9 - $51.08 $431,049 - $630,889	12,351 Added 101.17%	24,559 $857,000
Q3 2020 Nov 05, 2020	BUY	$32.95 - $50.25 $402,253 - $613,452	12,208 New	12,208 $609,000

26.5K

Ticker FMTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 47,860,400
Market Cap $958M
Description
Forma Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on development and commercialization of novel therapeutics for treatment of rare hematologic diseases and cancers. Its core product candidates for development include FT-4202, which is Phase 1 trial for the treatment of sickle cell disease and other hemoglobin...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.